ACM
CMPX icon

ADAR1 Capital Management’s Compass Therapeutics CMPX Stock Holding History

ADAR1 Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$735K Hold
139,000
– – 0.04% 183
2025
Q4 		$746K Buy
139,000
+89,000
+178% +$411K 0.05% 157
2025
Q3 		$175K Buy
50,000
+25,000
+100% +$79K 0.02% 183
2025
Q2 		$65K Buy
+25,000
New +$51.6K 0.01% 186
2024
Q2 		– Sell
-10,206
Closed -$20.2K – 282
2024
Q1 		$20.2K Buy
+10,206
New +$17.6K ﹤0.01% 216

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ADAR1 Capital Management's CMPX Position: Q1 2026 in Review

ADAR1 Capital Management held its Compass Therapeutics (CMPX) position steady in Q1 2026 at 139,000 shares worth $735K. The position accounts for 0.04% of the portfolio, ranked #183.

ADAR1 Capital Management first reported a position in CMPX in Q1 2024 and has held it in 5 quarters since. The position peaked at $746K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • ADAR1 Capital Management held 139,000 shares of Compass Therapeutics worth $735K as of Q1 2026.
  • ADAR1 Capital Management left its Compass Therapeutics share count unchanged in Q1 2026.
  • Compass Therapeutics made up 0.04% of ADAR1 Capital Management's portfolio in Q1 2026, its #183 holding.
  • ADAR1 Capital Management first reported a position in Compass Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • ADAR1 Capital Management's Compass Therapeutics position peaked at $746K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.